As of Nov 20
| -1.04 / -1.52%|
The 13 analysts offering 12-month price forecasts for CRISPR Therapeutics AG have a median target of 80.00, with a high estimate of 107.00 and a low estimate of 28.00. The median estimate represents a +18.66% increase from the last price of 67.42.
The current consensus among 16 polled investment analysts is to Buy stock in CRISPR Therapeutics AG. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.